Mode
Text Size
Log in / Sign up
N/A N=26 Randomized Double-blind Treatment

Magnetic Stimulation to Treat VT Storm

Ventricular Tachycardia

Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Jul 2022
Primary outcome: Primary: Ventricular Tachycardia - Incidence of Ventricular Tachycardia on Inpatient Telemetry Monitoring — 7; 4 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Magstim SuperRapid (Device)
Age
Adult, Older Adult · 19+ yrs
Sex
All
Sponsor
University of Pennsylvania
Primary completion
Jun 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Ventricular Tachycardia - Incidence of Ventricular Tachycardia on Inpatient Telemetry Monitoring
7; 4
SECONDARY
Cardioversion - Incidence of ICD Therapies or External Defibrillation Following Stimulation on Device Interrogation or Telemetry
7; 4
SECONDARY
Number of Patients With Changes in ICD or Pacemaker Lead Impedances
0; 0
SECONDARY
Number of Patients With Changes in ICD or Pacemaker Lead Thresholds
0; 0
SECONDARY
Number of Patient With Changes in ICD or Pacemaker Lead Sensitivities
0; 0
SECONDARY
Local Effect From Stimulation - Patient Reported Local Discomfort on Visual Analog Scale (0-10)
0; 0
SECONDARY
Antiarrhythmic Drugs Used Post Stimulation - Incidence of Antiarrhythmic Drug Use Post Stimulation Per Inpatient Medical Record
2.3; 0.9
SECONDARY
Number of Patients With Changes in ECG Parameters
0; 0
SECONDARY
Number of Patients With Changes in Vital Signs
0; 0

Summary

Ventricular Tachycardia storm is a medical emergency characterized by three or more episodes of ventricular arrhythmia within 24 hours and associated with a significantly increased mortality and massive health resource utilization. Several therapies are utilized including sympathetic blockade (through deep sedation and beta blockers), antiarrhythmic drugs, implantable cardioverter defibrillator (ICD) reprograming where applicable, and catheter ablation. Despite standard intervention, mortality rates remain high and additional therapeutic options are actively being investigated. The overall objective of this proposal is to investigate whether transcutaneous magnetic stimulation designed to inhibit the left stellate ganglion can be used in this population. This is a single-center, randomized, sham-controlled trial to assess the efficacy of transcutaneous magnetic stimulation of the left stellate ganglion to treat patients with ventricular tachycardia storm.

Eligibility Criteria

Inclusion Criteria

  • ≥ 3 episodes of VT in 24 hours

Exclusion Criteria

  • Pregnancy
  • Implanted ventricular assist device
  • Metal implanted in head or neck (except the mouth)
  • Implanted medication pumps
  • Cochlear implant
  • Implanted brain stimulator
  • Ocular implant
  • History of active malignancy in region of stimulation (neck)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04043312). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search